Search results
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
Zacks via Yahoo Finance· 2 years agoSorrento Therapeutics’ SRNE subsidiary Scilex Holding Company recently received Fast Track...
Stock market news today: Stocks soar as investors look ahead to inflation data
Yahoo Finance· 1 year agoU.S. stocks gained Monday as Wall Street clawed back from a losing week and an upcoming inflation...
Why Sorrento Therapeutics Stock Is Crashing Today
Motley Fool· 1 year agoShares of the commercial-stage biopharma Sorrento Therapeutics (NASDAQ: SRNE) are having a tough time today. Specifically, the drugmaker's stock is down...
7 of the Best Contrarian Stocks to Buy When Investors Are Fearful
InvestorPlace via Yahoo Finance· 2 years agoContrarian investing is not easy, and it certainly takes a great deal of courage. Forbes defines...
Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today
Motley Fool· 2 years agoThe back half of 2022 is already shaping up to be a stock picker's market. Today's mixed trading...
Why Shares of Scilex Slumped This Week
Motley Fool· 1 year agoShares of Scilex Holding (NASDAQ: SCLX) fell 27.8% this week as of early Friday afternoon, according to data provided by S&P Global Market Intelligence....
Why Sorrento Therapeutics' Shares Tumbled 23.4% in September
Motley Fool· 2 years agoWhat happened Shares of Sorrento Therapeutics (NASDAQ: SRNE), a biotech company that specializes in...
2 Penny Stocks That Could Make You Filthy Rich
Motley Fool· 2 years agoStocks under $5 a share (aka penny stocks) are rarely worth considering as an investment vehicle. Companies that occupy this portion of the equity price...
Wall Street Thinks These 2 Penny Stocks Could Go Parabolic
Motley Fool· 1 year agoConcerns about interest rate hikes, supply chain kinks, geopolitical unrest, and of course inflation...
10 Stocks to Sell Before They Die
InvestorPlace via Yahoo Finance· 2 years agoThis article is excerpted from Tom Yeung’s Profit & Protection newsletter dated July 28, 2022. To make sure you don’t miss any of Tom’s picks, subscribe...
